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Dialysis is a rapidly growing treatment of end-
stage renal failure (ESRD). Since transplantation is
the only way out of ESRD and the number of organ
donors is woefully small, this treatment modality
will grow in the coming years. It is estimated that
there are currently more than one million patients
on some form of dialysis world-wide, and that 80–
85% of these are in Europe, the USA and Japan. In
these countries there will also be a rapid increase
of dialysis in the future. An estimate for numbers
on dialysis in Canada is given in Table 1 [1].
The economic changes occurring in the devel-
oping countries will result in a rapid increase of
dialysis patients in these areas also. However, in
these countries health care will not be adequate,
conditions of hygiene are low, and cost considera-
tions are important.
Infections being the most common complication
of dialysis, it is important to have a proper
approach to their management. In the last few
years three clinical guidelines have dealt with
the problem [2–4]. They describe the current man-
agement of infections.
In this article the changes expected, or already
underway, in dialysis methodology and their
expected impact on infections are discussed.
B I O F I L M
Biofilm, an almost ubiquitous slimy layer formed
by almost all micro-organisms on surfaces, is a
puzzling phenomenon [5,6]. While certain micro-
organisms show increased ability to form it (coa-
gulase-negative staphylococci, Pseudomonas sp.)
the pathogenic role of these biofilms is still under
discussion. They are a potential source of infection,
particularly of the chronic or recurrent type. The
slimy layer gives the micro-organisms protection
against antibiotics.
Research on the prevention of biofilm formation
is centerd on materials resistant to biofilm (not
very successful); antibacterial coating[7] (effective
in the short run); and therapeutic antibiotics to kill
biofilms [8] (difficult to achieve).
H E M O D I A L Y S I S
Access site [9]
An arteriovenous (AV) fistula (Cimino) shows the
lowest rates of infections. This is therefore the
recommended access method [10]. Polytetrafluor-
oethylene (PTFE) grafts have a higher infection
rate and are more resistant to antibiotic therapy.
Surgical graft revision is often required. Central
vascular catheters are used more often, not only for
acute haemodialysis, but also for more permanent
access [11]. They present special problems [12].
Meticulous exit-site care is necessary for long-term
use. Their advantage is that often they can be
changed over a guidewire [13]. Prophylaxis of
infections is being attempted by using antibiotic
locks. Infections manifest themselves in bactere-
mias, which, in the case of Staphylococcus aureus the
most common causative organism, may lead to
secondary abscesses, endocarditis, etc.
The search for novel access sites resulted in
subcutaneous injection chambers [14,15]; initial
clinical studies of these are in progress.
N E W A P P R O A C H E S T O
H E M O D I A L Y S I S
Kidney Diseases Outcomes Quality Initiative (K/
DOQI) guidelines [10] placed strong emphasis on
the adequacy of dialysis which leads to better
patient survival. This can be achieved by longer
hours on hemodialysis. The increase in hours is
inconvenient to patients; therefore the frequency
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of dialysis was investigated [16,17]. Prelimi-
nary results are very encouraging. Since this
method doubles the penetration of access sites,
the frequency of infectious episodes is watched
carefully.
P R E V E N T I O N O F H E M O D I A L Y S I S
I N F E C T I O N S
Improving the hygiene conditions in hemodialysis
units produces a reduction in infectious episodes
[2,4]. Regular treatment of the exit site of central
line catheters requires special care [18]. The role of
S. aureus nasal carriers has been well documented
and approaches to reduce the risk have been
established [19].
P E R I T O N E A L D I A L Y S I S
Of the dialysis population, 15–30% is on peritoneal
dialysis. The question of equivalence of hemodia-
lysis versus peritoneal dialysis has been settled
[20]. They are equally efficacious, each having
advantages and disadvantages.
While initially peritoneal dialysis involved high
rates of peritonitis (1/3 peritonitis episodes/
patient month) it is not unusual to find units with
a rate of 1/36–1/48 patient months.
P E R I T O N E A L A C C E S S
There are many types of new catheters. It appears
that catheters with a double cuff have a slight
advantage over single-cuff catheters as far as infec-
tions are concerned. On the other hand, double-
cuff catheters require surgical implantation while
single-cuff catheters can be implanted by lapara-
scopic methods [21]. As far as the shape of the
catheter is concerned, there are no convincing
differences in infection rates.
M E T H O D S O F P E R I T O N E A L
D I A L Y S I S
The initial ‘spike’ method was slowly replaced by
the Y-tube or double-bag method (‘flush before
fill’) resulting in a significant reduction of infec-
tions [22]. More recently, automated peritoneal
dialysis (APD) started to gain ground [23]. In some
countries 30% of peritoneal dialysis patients are
on APD. As a consequence of trying to achieve
more efficient dialysis, continuous flow peritoneal
dialysis (CFPD) was introduced [24,25]. However,
a final judgment about this method has not yet
been made.
C O N N E C T I O N S Y S T E M S
There is still competition to devise a better con-
nection. The standard Luer lock system has been
modified to include more secure connections, with
disinfectant (providone) locked in the connection
site.
N E W D I A L Y S I S F L U I D S
New fluids have been introduced [26,27]. For mal-
nourished patients a dialysis fluid is available
containing an amino acid mixture which provides
an easy source for protein synthesis. While it is
relatively expensive, and can be used only once a
day, it is effective. A solution containing polyglu-
cose (icodextrin) instead of glucose is the osmotic
agent. It is useful to manage water transport where
normal solutions are failing.
New solutions are under development, where
the fluid’s acidity and osmolality are managed
more physiologically. It is expected that these
solutions are going to provide a more natural
environment, leading to longer preservation of
the transport capacity of the peritoneum. Also, it
Table 1 Estimate of dialysis increase in Canada between 1994 and 2005
1994 2005 Annual % increase
No. patients /106a No. patients /106 No. patients /106
Hemodialysis 5840 207.7 12 075 379.6 6.8 5.6
Peritoneal dialysis 3318 118.0 6555 206.1 6.4 5.2
Transplant 5904 210.0 12 874 404.7 7.3 6.1
Total 15 062 535.8 31 505 990.4 6.9 5.7
aIncidence per 106 of the population.
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is hoped that this better milieu will help in the
defence functions of the peritoneum.
I N F E C T I O N R A T E S
With the introduction of APD it was expected that
peritonitis rates would increase, since the system is
connected overnight and the patient may require
disconnection and reconnection. It is a closed sys-
tem, with the necessary safe connections. It does
not appear to increase the rate of peritonitis and
the distribution of organisms is the same as for the
double- bag system [28].
D I A G N O S I S A N D T R E A T M E N T
The formerly established diagnostic criteria (two
out of three criteria present) cell count in the
peritoneal fluid of >100 cells/mm3 with >50%
neutrophils and/or abdominal pain and rebound
tenderness and/or bacteria on culture proved to
be reliable and practical. Procedures for cultures
have been discussed previously [3]. One difficulty
in patients on APD is that there is no bag with
dwell time sufficient for the above diagnostic
criteria, which were established for standard 4–
6-h dwell times. Shorter times may give mis-
leadingly low cell counts and false-negative
cultures.
It is therefore necessary for appropriate diag-
nosis to provide a dwell time of 4–6 h either by
prolonging the last (night) dwell and collecting the
last drain or by having the patient carry an extra
4–6-h extra day-dwell. Laboratory diagnosis in
the usual manner should be performed on such
drainage fluids.
Antibiotic therapy has shifted in recent years to
single intraperitoneal daily doses [29,30].
Decreasing residual renal function is an inde-
pendent predictor of dialysis outcome. Therefore
preserving residual function is a necessity. Ami-
noglycoside use is the most common reason for
decrease of residual renal function. The committee
on treatment of peritonitis in CAPD patients
recommended the treatment [3] that is briefly out-
lined below.
(1) Intermittent (once daily) therapy is preferred.
(2) Patients with <100 mL 24-h urine should be
given on 0.6 mg/kg (50 mg for body weight
>60 kg, 40 mg for body weight <60 kg) ami-
noglycoside and 15 mg/kg cefazolin once
daily, with a dwell time of at least 3–4 h.
(3) Patients with >100 mL 24-h urine should be
given on 1500 mg ceftazidime and 20 mg/kg
(1.5 g) cefazolin once daily with a dwell time of
at least 3–4 h.
(4) Vancomycin is still recommended only for
methicillin-resistant organisms.
(5) Antibiotics should be adjusted when sensitiv-
ities are available.
(6) For patients on automated peritoneal dialysis
the antibiotics should be placed in an extra
day-dwell of appropriate volume for 4–6 h to
assure appropriate antibiotic transfer.
P R E V E N T I O N O F P E R I T O N I T I S
The importance of the reduction of S. aureus exit-
site infection as a cause of peritonitis has been
stressed previously [18]. Recent clinical reports of
the use of mupirocin ointment at the exit site [31–
33] further strengthened the recommendation to
follow this practice.
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